Search
Polycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.
Cocaine
go.drugbank.com/drugs/DB00907ApprovedIllicitInvestigationalCocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalBy inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.
Phenol
go.drugbank.com/drugs/DB03255ApprovedInvestigationalIt is active against a wide range of micro-organisms including some fungi and viruses, but is only slowly effective against spores. Phenol has been used to disinfect skin and to relieve itching. … During the second world war, phenol injections were used as a means of execution by the Nazis. Phenol is a toxic compound whose vapours are corrosive to the skin, eyes, and respiratory tract.
Mebutamate
go.drugbank.com/drugs/DB06797ApprovedMebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a
Gefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalIt is marketed by AstraZeneca under the trade name Iressa.
Ceftizoxime
go.drugbank.com/drugs/DB01332ApprovedWithdrawnA semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.
Entecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalIt was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
Phenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnIt was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.